Literature DB >> 27979439

Albuminuria is associated with greater copeptin concentrations in men with type 1 diabetes: A brief report from the T1D exchange Biobank.

Petter Bjornstad1, Richard J Johnson2, Janet K Snell-Bergeon3, Laura Pyle4, Asa Davis5, Nicole Foster6, David Z Cherney7, David M Maahs8.   

Abstract

BRIEF
SUMMARY: Vasopressin exerts important cardio-renal effects, but remains problematic to measure. Copeptin is a more stable peptide derived from the same precursor molecule. In this case-control study from the Type 1 Diabetes Exchange (T1DX) Biobank registry, men with T1D and albuminuria had greater copeptin concentrations than men with normoalbuminuria.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Albuminuria; Copeptin; Diabetic kidney disease; Glomerular filtration rate; Type 1 diabetes

Mesh:

Substances:

Year:  2016        PMID: 27979439      PMCID: PMC5303164          DOI: 10.1016/j.jdiacomp.2016.11.015

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  14 in total

Review 1.  Hydration and Chronic Kidney Disease Progression: A Critical Review of the Evidence.

Authors:  William F Clark; Jessica M Sontrop; Shi-Han Huang; Louise Moist; Nadine Bouby; Lise Bankir
Journal:  Am J Nephrol       Date:  2016-05-03       Impact factor: 3.754

Review 2.  Vasopressin: a novel target for the prevention and retardation of kidney disease?

Authors:  Lise Bankir; Nadine Bouby; Eberhard Ritz
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

3.  Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.

Authors:  Kunihiro Matsushita; Marije van der Velde; Brad C Astor; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh; Ron T Gansevoort
Journal:  Lancet       Date:  2010-05-17       Impact factor: 79.321

Review 4.  Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association.

Authors:  Sarah D de Ferranti; Ian H de Boer; Vivian Fonseca; Caroline S Fox; Sherita Hill Golden; Carl J Lavie; Sheela N Magge; Nikolaus Marx; Darren K McGuire; Trevor J Orchard; Bernard Zinman; Robert H Eckel
Journal:  Circulation       Date:  2014-08-11       Impact factor: 29.690

5.  The T1D Exchange clinic registry.

Authors:  Roy W Beck; William V Tamborlane; Richard M Bergenstal; Kellee M Miller; Stephanie N DuBose; Callyn A Hall
Journal:  J Clin Endocrinol Metab       Date:  2012-09-20       Impact factor: 5.958

6.  Plasma vasopressin in uncontrolled diabetes mellitus.

Authors:  R L Zerbe; F Vinicor; G L Robertson
Journal:  Diabetes       Date:  1979-05       Impact factor: 9.461

7.  Vasopressin increases urinary albumin excretion in rats and humans: involvement of V2 receptors and the renin-angiotensin system.

Authors:  Pascale Bardoux; Daniel Georges Bichet; Hélène Martin; Yves Gallois; Michel Marre; Marie-Françoise Arthus; Michèle Lonergan; Nicole Ruel; Nadine Bouby; Lise Bankir
Journal:  Nephrol Dial Transplant       Date:  2003-03       Impact factor: 5.992

8.  Vasopressin increases glomerular filtration rate in conscious rats through its antidiuretic action.

Authors:  N Bouby; M Ahloulay; E Nsegbe; M Déchaux; F Schmitt; L Bankir
Journal:  J Am Soc Nephrol       Date:  1996-06       Impact factor: 10.121

9.  Plasma Copeptin, AVP Gene Variants, and Incidence of Type 2 Diabetes in a Cohort From the Community.

Authors:  Ronan Roussel; Ray El Boustany; Nadine Bouby; Louis Potier; Frédéric Fumeron; Kamel Mohammedi; Beverley Balkau; Jean Tichet; Lise Bankir; Michel Marre; Gilberto Velho
Journal:  J Clin Endocrinol Metab       Date:  2016-04-06       Impact factor: 5.958

10.  Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular and all-cause mortality in patients with type 2 diabetes (ZODIAC-31).

Authors:  Ineke J Riphagen; Wendy E Boertien; Alaa Alkhalaf; Nanne Kleefstra; Ron T Gansevoort; Klaas H Groenier; Kornelis J J van Hateren; Joachim Struck; Gerjan Navis; Henk J G Bilo; Stephan J L Bakker
Journal:  Diabetes Care       Date:  2013-06-11       Impact factor: 19.112

View more
  6 in total

1.  SGLT2 inhibition increases serum copeptin in young adults with type 1 diabetes.

Authors:  Y Lytvyn; P Bjornstad; A Katz; S K Singh; L C Godoy; L T Chung; C L Vinovskis; L Pyle; R Roussel; B A Perkins; D Cherney
Journal:  Diabetes Metab       Date:  2019-12-06       Impact factor: 6.041

Review 2.  The New Biology of Diabetic Kidney Disease-Mechanisms and Therapeutic Implications.

Authors:  Yuliya Lytvyn; Petter Bjornstad; Daniel H van Raalte; Hiddo L Heerspink; David Z I Cherney
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871

3.  Elevated copeptin, arterial stiffness, and elevated albumin excretion in adolescents with type 1 diabetes.

Authors:  Pattara Wiromrat; Petter Bjornstad; Carissa Vinovskis; Linh T Chung; Carlos Roncal; Laura Pyle; Miguel A Lanaspa; Richard J Johnson; David Z Cherney; Tyler K Reznick-Lipina; Franziska Bishop; David M Maahs; Raj Paul Wadwa
Journal:  Pediatr Diabetes       Date:  2019-08-29       Impact factor: 4.866

4.  Vasopressin associated with renal vascular resistance in adults with longstanding type 1 diabetes with and without diabetic kidney disease.

Authors:  Federica Piani; Trenton Reinicke; Yuliya Lytvyn; Isabella Melena; Leif E Lovblom; Vesta Lai; Josephine Tse; Leslie Cham; Andrej Orszag; Bruce A Perkins; David Z I Cherney; Petter Bjornstad
Journal:  J Diabetes Complications       Date:  2020-11-26       Impact factor: 2.852

Review 5.  Role of sodium-glucose cotransporter 2 inhibition to mitigate diabetic kidney disease risk in type 1 diabetes.

Authors:  Daniël H van Raalte; Petter Bjornstad
Journal:  Nephrol Dial Transplant       Date:  2020-01-01       Impact factor: 5.992

Review 6.  Novel Cardiovascular Risk Factors in Patients with Diabetic Kidney Disease.

Authors:  Christodoula Kourtidou; Maria Stangou; Smaragdi Marinaki; Konstantinos Tziomalos
Journal:  Int J Mol Sci       Date:  2021-10-17       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.